SUO held in conjunction with the AUA Annual Meeting
Saturday, May 19, 2012
Omni Hotel at CNN Center | Grand Ballroom D & E | Atlanta, GA

SUO Reception & Dinner
Georgia Aquarium, Atlantic Room
**SUO held in conjunction with the AUA Annual Meeting**  
Saturday, May 19, 2012  
Omni Hotel at CNN Center  
Grand Ballroom D & E  
Atlanta, GA

The morning session is a combined meeting of the Society of Urologic Oncology (SUO) and the Society of Basic Urologic Research (SBUR)

---

**SUO/SBUR JOINT MEETING (MORNING PROGRAM)**  
**PERSONALIZED MEDICINE: ARE WE THERE YET?**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:55 a.m. – 8:00 a.m.</td>
<td>Introduction and Welcome</td>
<td>Vinata Lokeshwar, PhD</td>
<td>University of Miami</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Edward Messing, MD</td>
<td>University of Rochester</td>
</tr>
<tr>
<td>8:00 a.m. – 8:20 a.m.</td>
<td>Targeting Proteolytic, Chemokine and Growth-Factor Related Pathways in Prostate Cancer Bone Metastasis</td>
<td>Michael Cher, MD</td>
<td>Wayne State University</td>
</tr>
<tr>
<td>8:20 a.m. – 8:25 a.m.</td>
<td>Questions &amp; Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:25 a.m. – 8:45 a.m.</td>
<td>N-Cadherin and Associated EMT Mediates Castration and Chemotherapy Resistance in Advanced Prostate Cancer</td>
<td>Robert Reiter, MD</td>
<td>University of California, Los Angeles</td>
</tr>
<tr>
<td>8:45 a.m. – 8:50 a.m.</td>
<td>Questions &amp; Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:50 a.m. – 9:10 a.m.</td>
<td>Resistance to VEGF Targeted Therapy: Mechanisms and Drug Development Opportunities</td>
<td>Michael Atkins, MD</td>
<td>Beth Israel Deconess Medical Center</td>
</tr>
<tr>
<td>9:10 a.m. – 9:15 a.m.</td>
<td>Questions &amp; Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**SUO SCIENTIFIC MEETING (AFTERNOON PROGRAM)**  
**Location: Grand Ballroom D & E**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:35 a.m. – 9:40 a.m.</td>
<td>Questions &amp; Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:40 a.m. – 10:00 a.m.</td>
<td>miRNA Targets in Personalized Management of Urological Malignancies</td>
<td>Rajiv Dahiya, PhD</td>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>10:00 a.m. – 10:05 a.m.</td>
<td>Questions &amp; Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:05 a.m. – 10:25 a.m.</td>
<td>Inflammation and Prostate Cancer Development</td>
<td>Timothy Ratliff, PhD</td>
<td>Purdue University</td>
</tr>
<tr>
<td>10:25 a.m. – 10:30 a.m.</td>
<td>Questions &amp; Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**III. THE COFFEY LECTURESHIP**  
Moderators: Vinata Lokeshwar, PhD  
Edward Messing, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m. – 11:25 a.m.</td>
<td>Androgens, Nuclear Structure and the Systemic Treatment of Prostate Cancer</td>
<td>William Nelson, MD</td>
<td>Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:25 a.m. – 12:25 p.m.</td>
<td>SUO Business Meeting Luncheon (Members Only)</td>
<td></td>
<td>Location: International Luncheon</td>
</tr>
</tbody>
</table>

---

**PROSTATE CANCER SCREENING**  
**Location: International Ballroom ABC**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 p.m. – 12:45 p.m.</td>
<td>Welcome and Introductions</td>
<td>Edward M. Messing, MD</td>
<td>University of Rochester Medical Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Presentation of Prostate Cancer Foundation Awards</td>
<td>Stuart Holden, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Program Overview</td>
<td>Badar M. Mian, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 p.m. – 1:00 p.m.</td>
<td>PSA Screening</td>
<td>Gerald L. Andriole, Jr., MD</td>
<td>Washington University Medical School</td>
</tr>
<tr>
<td>1:00 p.m. – 1:15 p.m.</td>
<td>How to Minimize Harm from Screening (Reducing Morbidity)</td>
<td>Eric A. Klein, MD</td>
<td>Cleveland Clinic</td>
</tr>
<tr>
<td>1:15 p.m. – 1:20 p.m.</td>
<td>Questions &amp; Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:20 p.m. – 1:50 p.m.</td>
<td>Whitmore Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Tsunami of the Baby Boom Generation and Urologic Oncology</td>
<td>Alvaro Morales, MD</td>
</tr>
</tbody>
</table>
GU CANCERS IN THE ELDERLY (> AGE 75)

1:50 p.m. – 2:05 p.m.  Burden of Disease (Incidence, Mortality): Prevalence of Co-Morbidities  Badrinath R. Konety, MD, MBA  University of Minnesota

2:05 p.m. – 2:15 p.m.  Implications for General Anesthesia  Christopher J. Jankowski, MD  Mayo Clinic

2:15 p.m. – 2:25 p.m.  Evaluating the Elderly and Frail Patient  Supriya G. Mohile, MD  University of Rochester Medical Center

2:25 p.m. – 2:30 p.m.  Questions & Discussion

CHALLENGES OF SYSTEMIC THERAPY IN THE ELDERLY

2:30 p.m. – 2:40 p.m.  Targeted Therapies  Primo N. Lara, MD  UC Davis Comprehensive Cancer Center

2:40 p.m. – 2:50 p.m.  Chemotherapy  Gary R. MacVicar, MD  Northwestern Memorial Hospital

2:50 p.m. – 2:55 p.m.  Questions & Discussion

PROSTATE CANCER IN THE ELDERLY

2:55 p.m. – 3:05 p.m.  Who is Appropriate for Definitive Therapy?  Peter C. Albertsen, MD  University of Connecticut Health Center

3:05 p.m. – 3:20 p.m.  Role of ADT and Newer Treatments for Castrate Resistant Disease in the Elderly  Neal D. Shore, MD  Carolina Urologic Research Center

3:20 p.m. – 3:25 p.m.  Questions & Discussion

LOCALIZED RENAL CANCER IN THE ELDERLY

3:25 p.m. – 3:40 p.m.  Partial Nephrectomy vs. Radical vs. Ablation: Role of Renal Dysfunction  Steven C. Campbell, MD  Cleveland Clinic

3:40 p.m. – 3:50 p.m.  Role of Expectant Management  Michael A.S. Jewett, MD  Princess Margaret Hospital

3:50 p.m. – 4:00 p.m.  Questions & Discussion

MUSCLE INVASIVE BLADDER CANCER— A DISEASE OF THE ELDERLY

4:00 p.m. – 4:15 p.m.  Radical Cystectomy +/- Chemotherapy  Harry W. Herr, MD  Memorial Sloan-Kettering Cancer Center

4:15 p.m. – 4:25 p.m.  Chemo Rx + Radiation Therapy  William U. Shipley, MD  Massachusetts General Hospital

4:25 p.m. – 4:30 p.m.  Questions & Discussion

4:30 p.m. – 4:50 p.m.  Role of 5 ARIs in Prostate Cancer Prevention  Ian M. Thompson, Jr., MD  University of Texas Health Science Center

4:45 p.m. – 4:50 p.m.  Questions & Discussion

5:00 p.m.  Adjourn

SATURDAY, MAY 19, 2012

SUO/SBUR Joint Meeting (Morning Program)

Omni Hotel at CNN Center
Location: Grand Ballroom D & E
7:55 a.m. – 11:25 a.m.

SUO Business Meeting Luncheon (Members Only)
Omni Hotel at CNN Center
Location: International Ballroom ABC
11:25 a.m. – 12:25 p.m.

SUO Scientific Meeting (Afternoon Program)
Omni Hotel at CNN Center
Location: Grand Ballroom D & E
12:30 p.m. – 5:00 p.m.

SUO Reception & Dinner
Georgia Aquarium
Location: Atlantic Room
Attire: Business casual
6:30 p.m. – 10:00 p.m.

*Separate registration is required
SUO/SBUR JOINT MEETING EDUCATIONAL NEEDS
(MORNING PROGRAM)

Personalized medicine is the new buzz word in medical practice. From profiling of patients’ genome, proteome and metabolome to targeted therapy, researchers, clinicians and most importantly, internet savvy patients, are demanding personalized medicine. This session will focus on new approaches to individualized treatment and making prognostic predictions.

Participants will learn about the current research directions related to gene/protein-based profiling approaches for designing diagnostic and prognostic tests and targeted therapy. New clinical trials that are underway based on targeted therapy and how the new findings driving individualized treatments for improving patient outcomes.

SUO/SBUR EDUCATIONAL OBJECTIVES
(MORNING PROGRAM)

At the conclusion of the session, participants should be able to:
• Report foundational knowledge in the areas of next generation of tumor markers, as well as individualized treatments for various urologic cancers.
• Employ practical applications of basic research findings towards designing treatments tailored to target a patient’s cancer.
• Utilize discussion of new research directions to improve outcome through novel personalized tests and treatments for a wide range of urologic malignancies.

SUO SCIENTIFIC MEETING EDUCATIONAL NEEDS
(AFTERNOON PROGRAM)

• There is a deficit of knowledge about prostate cancer screening and its benefits and harms, especially in light of recently released clinical trial data.
• There is a deficit of competence related to treatment of kidney cancer, such as a radical nephrectomy performed too often when a partial nephrectomy may be more appropriate.
• Performance deficit is noted for penile and urethral cancers despite the knowledge and guidelines regarding straightforward diagnostic procedures.
• Systemic therapy is omitted or administered infrequently in many elderly patients who could otherwise benefit from it due to lack of knowledge about its side effects and alternatives.
• There is a lack of understanding of the special considerations in the elderly patient regarding their risks of anesthesia, sometimes resulting in non-curative treatment.

SUO SCIENTIFIC MEETING EDUCATIONAL OBJECTIVES
(AFTERNOON PROGRAM)

After attending this meeting, attendees should be able to:
• Identify the benefits of screening for prostate cancer in terms of number of deaths prevented and the price of population-based screening.
• Estimate the cost of screen-detected early stage cancer vs. non-screen-detected advanced cancers.
• Employ an active surveillance or watchful waiting program for the appropriate patients
• Identify the risk of morbidity and mortality in the elderly patients with GU cancers
• Apply the knowledge regarding surgical and systemic therapy in elderly patients, especially those with bladder and kidney cancer.
• Utilize less radical surgical resection in appropriately selected patients with bladder and kidney cancers
• Integrate the recommendations regarding penile and urethral cancers in order to prevent delays in diagnosis and treatment.

Accreditation: The American Urological Association Education & Research, Inc. (AUWER) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association Education & Research, Inc. designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The SUO/SBUR Joint Meeting (Morning Program) is designated for a maximum of 3.00 AMA PRA Category 1 Credits™.

The SUO Scientific Meeting (Afternoon Program) is designated for a maximum of 4.00 AMA PRA Category 1 Credits™.

The AUWER takes responsibility for the content, quality, and scientific integrity of this CME activity.

AUWER Disclosure Policy: As a provider accredited by the ACCME, the AUWER must ensure balance, independence, objectivity and scientific rigor in all its activities.

All faculty participating in an educational activity provided by the AUWER are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUWER must determine if the faculty’s relationships may influence the educational content with regard to exposition or conclusion and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent faculty with relevant financial relationships from serving as faculty, but rather to provide members of the audience with information on which they can make their own judgments.

Off-Label or Unapproved Use of Drugs or Devices: It is the policy of the AUWER to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUWER.

Evidence Based Content: As a provider of continuing medical education accredited by the ACCME, it is the policy of the AUWER to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Special Assistance/Dietary Needs: The American Urological Association Education & Research, Inc. (AUWER), an organization accredited for Continuing Medical Education (CME), complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call (847) 264-5901.
MARK YOUR CALENDAR

13th Annual SUO Winter Meeting

to discuss current topics and strategies in Urologic Oncology

Wednesday, November 28 – Friday, November 30, 2012

YUO Dinner: Wednesday, November 28th
SUO Annual Banquet: Thursday, November 29th

Bethesda North Marriott Hotel & Conference Center
5701 Marinelli Road
Bethesda, MD 20852
Phone: (301) 822-9200
Fax: (301) 822-9201

SUO is happy to provide discounted room rates of $189.00, plus applicable tax at the host hotel. The block may sell out prior to the hotel deadline of November 3, 2012; therefore, attendees are strongly encouraged to make early reservations.

Visit our website at www.suonet.org for updates on the program agenda and meeting registration.

CALL FOR ABSTRACTS: July 1, 2012

ABSTRACTS DEADLINE: August 13, 2012
THANK YOU TO THE SUO 2011 – 2012 PROMOTIONAL PARTNERS

PLATINUM LEVEL

janssen

GOLD LEVEL

AMGEN®

Dendreon

Targeting Cancer, Transforming Lives®

SILVER LEVEL

ENDO

PHARMACEUTICALS

BRONZE LEVEL

ALLERGAN

BAYER

SOCIETY OF UROLOGIC ONCOLOGY

2012